Alivus Life Sciences Q1FY27 PAT Grows 32% YoY to ₹160 Crore, Revenue Up 6.4%
Alivus Life Sciences reported Q1FY27 results with PAT growing 31.8% YoY to ₹1,601 million and revenue up 6.4% YoY to ₹6,404 million. EBITDA margins reached 36.6%. The company expects FY27 revenue growth of 10%-12% and maintains EBITDA margins of 30%-32%. Capex includes facility expansions in Solapur and a new R&D centre in Taloja.
The announcement includes robust financial performance with significant growth in key metrics, positive management commentary on future outlook, and details on ongoing capital expenditure for capacity expansion and R&D, all of which are material to investors.
The company reported strong year-on-year growth in PAT and revenue, improved margins, and a positive outlook for the fiscal year, along with significant free cash flow generation and a net debt-free status.
Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited) has announced its financial results for the first quarter ended June 30, 2026. The company reported its highest-ever Profit After Tax (PAT) of ₹1,601 million (approximately ₹160 crore), marking a significant year-on-year growth of 31.8%. The PAT margins improved substantially to 25.0%, an increase of 480 basis points compared to the previous year.
Revenue from operations for Q1FY27 reached ₹6,404 million (approximately ₹640 crore), reflecting a year-on-year growth of 6.4%. This growth was primarily driven by a robust performance in the non-GPL (Generics Product List) business, which saw an impressive increase of 26.5% year-on-year. EBITDA for the quarter stood at ₹2,341 million (approximately ₹234 crore), a growth of 29.1% year-on-year, with margins at a healthy 36.6%. This expansion in margins was attributed to a favourable product mix, successful new product launches, and the realization of operating leverage benefits.
The company also generated a strong free cash flow of ₹901 million (approximately ₹90 crore) during Q1FY27. As of June 30, 2026, Alivus Life Sciences maintained a healthy liquidity position with Cash and Cash Equivalents (including short-term investments) amounting to ₹8,802 million (approximately ₹880 crore). The company remains net debt-free.
Dr. Yasir Rawjee, MD & CEO, expressed satisfaction with the positive start to FY27, highlighting the resilience of the business model and strong execution, particularly in the non-GPL segment. He expressed confidence in sustaining momentum and achieving revenue growth of 10%-12% in FY27, while maintaining EBITDA margins between 30%-32%, despite muted growth expected in the GPL business. Tushar Mistry, CFO, emphasized the strong operational performance and disciplined execution contributing to the record EBITDA margins and a healthy balance sheet.
Additional highlights include cumulative DMF/CEP filings reaching 617 as of June 30, 2026. The High Potency API (HP API) portfolio has 29 APIs in the active grid, with 13 products validated. Capex updates include the ongoing construction of Phase 1 and Phase 2 of the Solapur facility, expected to be completed in Q3 FY27 and Q4 FY27, respectively. A new R&D facility is also under construction in Taloja, Navi Mumbai, to focus on advanced research areas.
What to do with a filing like this
Alivus Life Sciences Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Alivus Life Sciences Limited. Read the original for the full detail.